Categories
Business Digital - AI & Apps Education Lifestyle Technology

A look at the challenges Amazon Prime Video faces as it plans to show ads, also to include large brands 

—  The e-commerce giant must provide more high-quality content and court advertisers that don’t sell products on its platform, experts say

 

 

Patrick Coffee / Wall Street Journal:

The arrival of ads on Amazon Prime Video this month is expected to upend the already crowded streaming television market in the U.S. But it also won’t be an entirely smooth transition for Amazon.

 

The e-commerce giant is now the world’s third-largest digital ad seller, behind tech companies

Action series “Reacher” was the most-viewed title on Amazon Prime in 2023, according to Amazon. CREDIT: Brooke Palmer/Prime Video
Meta Platforms, with ad revenue surpassing $12 billion in the third quarter, up 26% from the period a year earlier. Its data and insights on millions of customers give Prime Video a long-term advantage by allowing marketers to target ads based on variables from shopping history to location.

 

Amazon will generate roughly $5.2 billion in additional annual revenue through Prime Video ad sales and the $2.99 monthly surcharge that subscribers can pay to avoid the ads, according to a recent Morgan Stanley research note. Roughly a third of Prime subscribers are expected to opt for the ad-free version, Bank of America analysts say.

Still, the company faces significant challenges as it enters a market where streaming rivals with large footprints in traditional media, such as Walt Disney and WarnerBros. Discovery, and even Netflix, a late arrival to ad sales, enjoy more established relationships with the advertisers that still spend the bulk of their money on broadcast TV. Amazon must convince the world’s largest brands, and the agencies that manage their budgets, to spend big on Prime Video despite a plethora of alternative ways to reach consumers and uncertainty regarding returns on their investments and threats to their market share.

 

“The dollars that are migrating into this opportunity are still tethered, in many ways, to traditional TV buying as opposed to digital ad buying,” said Andrew Lipsman, founder of consulting firm Media, Ads + Commerce. “Right now, Amazon is stronger on the digital advertiser front, but this is all new territory for them. They have plenty of speed bumps along the way.”

 

 

Read More

 

 

Techmeme

Categories
Business Digital - AI & Apps Education Technology

StatCounter: Bing ended 2023 with 3.4% global search market share, up less than one percentage point after ChatGPT

— Search engine has steadily increased usage but remains tiny

— Google meanwhile is racing to add its own AI enhancements

 

Jackie Davalos / Bloomberg:

 

 

When Microsoft Corp. announced it was baking ChatGPT into its Bing search engine last February, bullish analysts declared the move an “iPhone moment” that could upend the search market and chip away at Google’s dominance.

“The entire search category is now going through a sea change,” Chief Executive Officer Satya Nadella said at the time. “That opportunity comes very few times.”

Almost a year later, the sea has yet to change.

The new Bing — powered by OpenAI’s generative AI technology — dazzled internet users with conversational replies to queries asked in a natural way. But Microsoft’s search engine ended 2023 with just 3.4% of the global search market, according to data analytics firm StatCounter, up less than 1 percentage point since the ChatGPT announcement. (Google had 91.6%, Yandex 1.6%, and Yahoo 1%).

Google still dominates

Bing’s AI features have not shaken Google’s hold on the global search market

Source: StatCounter
Note: Data as of 12/31/2023. Other encompasses smaller search engines including Baidu and DuckDuckGo.

Bing has long struggled for relevance and attracted more mockery than recognition over the years as a serious alternative to Google. Multiple rebrandings and redesigns since its 2009 debut did little to boost Bing’s popularity. A month before Microsoft infused the search engine with generative AI, people were spending 33% less time using it than they had 12 months earlier, according to SensorTower.

The ChatGPT reboot at least helped reverse those declines. In the second quarter of 2023, US monthly active users more than doubled year over year to 3.1 million, according to a Bloomberg Intelligence analysis of SensorTower mobile app data. Overall, users were spending 84% more time on the search engine, the data show. By year-end, Bing’s monthly active users had increased steadily to 4.4 million, according to SensorTower.

To build on the momentum, Microsoft has been adding more AI tools to Bing. In October, the company integrated the latest version of OpenAI’s image-generating model, DALL-E 3. Visitors can use it to create realistic-looking images with simple text prompts.

The offering does nothing to enhance Bing’s search abilities. But its addition generated a spike in usage, according to Jordi Ribas, Microsoft’s corporate vice president of search and AI.

“We noticed an increase in usage by 10 times and that took us by surprise because if you think about it, DALL-E 2 was already quite good,” he said in an interview. “It really made a difference in the engagement and the users that came to our product.”

Yusuf Mehdi, Microsoft’s consumer chief marketing officer, declined to specify how many active users Bing has.

“Look, it’s still early days and new behaviors are being built,” he said. “We’re still learning new things, but have millions and millions of people using the new tools.”

Even as the Bing team adds crowd-pleasers, Google has been racing to develop its own AI tools. In May, it launched an experimental version of its search engine called the “search generative experience,” which delivers conversational responses atop the familiar list of links. Dubbed SGE for short, it’s still not widely available. However, Google plans to embed its most powerful large language model, Gemini, into SGE sometime this year.

The Alphabet Inc. division also retains considerable advantages. It has more than 90% of the market and is the default search engine on Apple Inc. hardware, including iPhones, giving Google crucial critical mass. The more people who use it, the more the search engine knows and the more Google can use that data to deliver and rank results in a way people find useful.

Bing’s ChatGPT boost

More people are using the search engine since it added generative AI features

Source: SensorTower

The retooling of search by both technology giants reflects a shared conviction that generative AI will fundamentally change the way people seek and receive answers online. For Microsoft, the shift is an opportunity to propel Bing forward. But the incremental gains so far make clear that buzzy AI features alone probably won’t transform it into a formidable search player.

“We are at the gold rush moment when it comes to AI and search,” said Shane Greenstein, an economist and professor at Harvard Business School, who has studied the commercialization of the internet. “At the moment, I doubt AI will move the needle because, in search, you need a flywheel: the more searches you have, the better answers are. Google is the only firm who has this dynamic well-established.”

 

 

 

— Techmeme

Categories
Culture Education Entertainment News International & World Lifestyle Perspectives

RASA Film Group launches collective focusing on strong female protagonists and positive Muslim characters

U.S.-based RASA Film Group is launching a film collective at the Sundance Film Festival.

 

The collective is actively exploring projects featuring strong female protagonists, narratives centered around social justice and stories that portray Muslim characters in positive and empowering roles.

 

RASA is in talks for future projects involving Muslim or Pakistani women talent such as Aizzah Fatima “(Americanish),” Mehreen Jabbar “(Farar),” Afia Nathaniel “(Dukhtar),” Mahnoor Euceph “(Eid Mubarak)” and Rehana Lew Mirza      (Wishtree).”

 

RASA is the brainchild of four partners of South Asian origin. Asad Butt is the founder and CEO of Rifelion Media, a film and podcast studio elevating diverse voices. He is the executive producer of the forthcoming “Ramadan America” film anthology and the “King of the World” podcast series. Butt is also a startup advisor and investor, primarily working with pet care and education founders and accelerator programs.

 

Sujit Chawla was a producer on the groundbreaking independent film “American Desi,” one of the seminal films chronicling the South Asian community in the U.S. Rohi Mirza Pandya is co-founder of Box Office Guru Media, Inc., a multicultural marketing agency, a creative producer and Diversity, Equity, Inclusion and Belonging consultant (DEIB) for Desipina Productions. She is also one of the founders of the first ever South Asian House at SXSW and Tribeca Festival in 2023 and was an executive producer on Oscar-qualified short film “Eid Mubarak” which played at last year’s Red Sea International Film Festival.

 

Atul Prashar individually, or as founding partner of KMH Group, has invested in more than 200 public-private tech-first companies in media, entertainment and sports. With previous stints in music and Bollywood, he has increasingly focused investing and advisory efforts towards global film projects that positively promote the South Asian diaspora.

 

“We are thrilled to be a diverse group of partners with a deep love for film and storytelling,” said Rohi Mirza Pandya. “Our combined wisdom and financial support will allow innovation in the industry and make a lasting impact.”

 

 

— Variety (EXCLUSIVE) 

Categories
Education Healthcare Lifestyle Local News News Now! Programs & Events Science

Bristol Myers Squibb Data at ASCO GU 2024 showcase transformative research in genitourinary cancer treatment

First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo (nivolumab and hyaluronidase) to be shared in a late-breaking oral presentation

Four-year data from CheckMate -9ER and unprecedented eight-year data from CheckMate -214 will confirm durable outcomes with Opdivo-based combinations for patients with advanced renal cell carcinoma

First disclosure of clinical outcomes from Phase 1 trial with BMS-986365 (CC-94676), the company’s first androgen receptor ligand-directed degrader in solid tumors from its targeted protein degradation platform, in metastatic castration-resistant prostate cancer

 

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #ASCOBristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from Jan. 25 to 27 in San Francisco, Calif., highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers, as well as showcasing potential new options and therapeutic platforms that may transform treatment paradigms across tumor types.

 

Data from 14 company-sponsored studies, investigator-sponsored studies and collaborations will be presented at the meeting.

The first presentation of data from the CheckMate -67T study will highlight the potential of a subcutaneous formulation of nivolumab co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) in advanced or metastatic clear cell renal cell carcinoma (RCC). Research to be shared will also add to the evidence supporting the use of Opdivo (nivolumab)-based combinations in patients with advanced RCC, including four-year follow-up data from the CheckMate -9ER trial and eight-year results from the CheckMate -214 trial. In addition, data will be presented on an investigational androgen receptor (AR) ligand-directed degrader (LDD; BMS-986365) in metastatic castration-resistant prostate cancer (mCRPC), providing validation for the targeted protein degradation platform in solid tumors and representing one of the company’s next waves of potential registrational assets.

 

“We are excited to present our research at ASCO GU 2024, which will demonstrate not only our long-standing leadership in oncology with our work in immunotherapy, but also our commitment to developing new assets and approaches to treating cancer from our differentiated research platforms such as targeted protein degradation in an effort to provide patients with better, long-term outcomes,” said Samit Hirawat, M.D., executive vice president and chief medical officer, Drug Development, Bristol Myers Squibb.

 

“These results simultaneously showcase the ongoing success of Opdivo-based combinations in metastatic disease and our contributions to the future of cancer treatment and research. We are especially eager to share data for the first time showing the potential of our subcutaneous formulation of a proven agent, and a new mechanism of action in a difficult-to-treat tumor type – both of which could have a tremendous impact on existing standards of care and the patient experience.”

 

Key data being presented by Bristol Myers Squibb at ASCO GU 2024 include:

  • First disclosure of pharmacokinetics, efficacy and safety results from the Phase 3 CheckMate -67T trial with subcutaneous nivolumab (nivolumab and hyaluronidase) being presented in a late-breaking oral session. This marks the first presentation of data evaluating subcutaneous nivolumab compared to its intravenous formulation.
  • Eight-year data from the Phase 3 CheckMate -214 study with Opdivo plus Yervoy (ipilimumab) showing ongoing survival and response benefits over sunitinib among intermediate- and poor-risk patients with advanced RCC, as well as among all randomized patients. These data represent the longest survival benefit vs. sunitinib reported in patients with previously untreated advanced or metastatic RCC.
  • Four-year follow-up data from the Phase 3 CheckMate -9ER trial evaluating Opdivo in combination with Exelixis’ CABOMETYX (cabozantinib). These data demonstrate meaningful, long-term efficacy benefits seen with the combination therapy over sunitinib and reinforce it as a standard of care for previously untreated advanced RCC.
  • First presentation of clinical outcomes from the company’s targeted protein degradation platform in solid tumors with Phase 1 data from BMS-986365 (CC-94676), an oral drug selectively targeting AR. BMS-986365 induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical activity in heavily pre-treated patients with mCRPC across wildtype, amplified and mutant AR status, highlighting this asset as the potential best-in-class AR-ligand directed degrader that may help overcome resistance to standard of care ARPIs in patients with mCRPC, a difficult-to-treat tumor type.

 

Summary of Presentations:

Abstract Title

Author

Presentation

Type/#

Session Title

Session

Date/Time (ET)

Prostate Cancer

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Dana Rathkopf

Poster

Abstract #134

Poster Bd. #F5

Poster Session A: Prostate Cancer

Thursday, January 25

2:30 PM – 4:00 PM

Renal Cell Carcinoma

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.

Saby George

Oral

Abstract #LBA360

Oral Abstract Session C: Renal Cell Cancer

Saturday, January 27

11:10 AM – 12:45 PM

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

Maria Teresa Bourlon

Rapid Oral

Abstract #362

Rapid Oral Abstract Session C: Renal Cell, Adrenal, and Testicular Cancers

Saturday, January 27

4:00 PM – 5:15 PM

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

Nizar Tannir

Rapid Oral

Abstract #363

Rapid Oral Abstract Session C: Renal Cell, Adrenal, and Testicular Cancers

Saturday, January 27

4:00 PM – 5:15 PM

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

Robert Motzer

Oral

Abstract #LBA358

Oral Abstract Session C: Renal Cell Cancer

Saturday, January 27

11:10 AM – 12:45 PM

Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.

Daniel Geynisman

Poster

Abstract #398

Poster Bd. #F22

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Saturday, January 27

10:00 AM – 11:00 AM

Urothelial Carcinoma

Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.

Daniel Geynisman

Oral

Abstract #528

Role of Immunotherapy in Advanced Urothelial Carcinoma: Sequencing, Pairing, Rechallenging

Friday, January 26

5:30 PM – 6:45 PM

Characteristics of patients (pts) with muscle-invasive urothelial carcinoma (MIUC) who received adjuvant nivolumab (NIVO) or adjuvant platinum-based chemotherapy (CHEMO) in the real-world (RW) setting.

Alex Chehrazi-Raffle

Poster

Abstract #565

Poster Bd. #E14

Poster Session B: Urothelial Carcinoma

Friday, January 26

2:30 PM – 4:00 PM

 

 

All abstracts except late-breaking abstracts will be available on ASCO’s digital program at 5:00 PM Eastern Time (ET) on January 22, 2024. All late-breaking abstracts will be available on ASCO’s digital program at 10:00 AM ET on their day of presentation at the meeting.

 

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position the company to approach cancer from every angle.

 

Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

 

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

 

Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

 

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. In September 2015, the Company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

 

About Yervoy

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. On March 25, 2011, the U.S. Food and Drug Administration (FDA) approved Yervoy 3 mg/kg monotherapy for patients with unresectable or metastatic melanoma. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries. There is a broad, ongoing development program in place for Yervoy spanning multiple tumor types.

 

INDICATIONS

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

OPDIVO® is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

OPDIVO® (nivolumab), in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

OPDIVO® (nivolumab), as a single agent, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum- containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

 

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune- mediated adverse reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

 

Immune-Mediated Pneumonitis

OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune- mediated pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.9%), and Grade 2 (2.1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune- mediated pneumonitis occurred in 7% (31/456) of patients, including Grade 4 (0.2%), Grade 3 (2.0%), and Grade 2 (4.4%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune- mediated pneumonitis occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%). In NSCLC patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, immune- mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.

In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12).

 

Immune-Mediated Colitis

OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).

In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated colitis occurred in 25% (115/456) of patients, including Grade 4 (0.4%), Grade 3 (14%) and Grade 2 (8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade 2 (3.7%).

Immune-Mediated Hepatitis and Hepatotoxicity

OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%), and Grade 2 (0.4%).

In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 15% (70/456) of patients, including Grade 4 (2.4%), Grade 3 (11%), and Grade 2 (1.8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade 2 (0.4%).

OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.

 

Immune-Mediated Endocrinopathies

OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis.

Contacts

Bristol Myers Squibb

Media Inquiries:
media@bms.com

Investors:
investor.relations@bms.com

Read full story here

Categories
Business Culture Economics Education Environment Healthcare International & World Lifestyle News Now! Perspectives Science

Beauty Hype: World’s most expensive bird droppings better than Botox!

Better than Botox: Many celebrities swear by it – over 400 years old recipe

NEW YORK — It’s supposed to work better than Botox, and after just a few minutes, you look 10 years younger. The story about it from “Asami Geisha” goes back to the 17th century and comes from Japan.

 

On special farms, nightingales produce valuable feces. The songbirds are fed exclusively with plant seeds. The feces contain the urea known in cosmetics and the enzyme guanine.

 

The nightingales’ feces are disinfected by ultraviolet light and then ground into a fine powder. The effect on the skin is instantaneous, and you’re left with a peachy complexion.

 

More than 300 years ago, geishas used “Asami Geisha” very successfully to regenerate and rebuild their skin bleached with lead and zinc.

 

Numerous celebrities all over the world admire the radiant skin of Japanese women. “Asami Geisha” is a pure natural cosmetic and does not require any chemical additives.

 

But if you want to enjoy these valuable cosmetics, you have to dig deep into your pocket. 50 ml of “Asami Geisha” costs an incredible  Euro 490. This makes “Asami Geisha” by far the most expensive bird droppings in the world.

 

British journalist Claudia Cornell tested the cosmetics for Mail Online. Her conclusion: “Even after two days, my skin looked radiant, and my girlfriend thought I had had Botox injections. I’m more than satisfied with the result.”

Source:

https://www.dailymail.co.uk/femail/article-2641957/The-cringe-inducing-facial-The-good-news-beats-Botox-The-bad-news-birds-mess.html

 

More information can be found at: www.asamigeisha.com

Categories
Culture Education Lifestyle Local News

D&R Greenway’s Johnson Education Center plans for artist talk and dessert reception

The public is invited to an artist talk and dessert reception on Thursday, Jan. 18 from 6:30 to  8:00 p.m. at D&R Greenway Land Trust’s Johnson Education Center, One Preservation Place, Princeton.

The Center encourages guests to take time to enjoy desserts, hot chocolate and cider and the works of other award-winning exhibiting artists including accomplished quilting artist, Deb Brockway; syndicated cartoon artist, author and playwright, Patrick McDonnell; and internationally acclaimed watercolorist James Fiorentino.  

Retired Princeton Day School teacher Liz Cutler, who led the school’s sustainability club to inspire students to observe and care for nature, is showing her botanical art in memory of her son, Isaac. Together, they walked Greenway Meadows park throughout his lifetime.

 

Liz, a self-taught artist, turned to the meditative art of collecting and pressing flowers into unique artistic expressions during his illness. She follows the Flower Pressers Ethos to ensure that anything she collects will do no harm to the species or environment.

I collect carefully, conscious of which flowers are ephemeral or how many are growing in a patch, and whether my taking one or two will matter to their survival. As I write this, the late afternoon light throws long shadows from trees now bare of their leaves, stark, winter closing in. It’s a different kind of beauty. There is nothing left to pick, but my closet desk drawers burst with labeled bags of sunshine: flowers and leaves, stems and stamens, even an intact eastern Swallowtail butterfly I found dead on the road.  They beg to be slowly and quietly drawn into a picture for a second life through art, to remind me that mine is a story of grace and gratitude, and to help others see, perhaps for the first time, the beauty of nature. I lose myself in the meditation.” Liz Cutler

 

Come to the Johnson Education Center to see Liz Cutler’s pressed flower art and hear about her inspiration and meditative creation process.  Enjoy desserts and warm beverages and experience  the feeling of being surrounded by a wildflower meadow in the cold of winter.  

 

In the event of inclement weather, the event will be rescheduled to Thursday, Jan. 25.  Registration begins at 6:30 p.m. followed by artist Liz Cutler’s presentation at 7:00 p.m. 

Art sales will benefit the land trust’s work to preserve and care for land, maintain public trails, and inspire a conservation ethic.

About D&R Greenway Land Trust: D&R Greenway Land Trust is an accredited nonprofit that has reached a new milestone of over 22,000 acres of land preserved throughout central New Jersey since 1989. By protecting land in perpetuity and creating public trails, it gives everyone the opportunity to enjoy the great outdoors. The land trust’s preserved farms and community gardens provide local organic food for residents of the region—including those most in need. Through strategic land conservation and stewardship, D&R Greenway combats climate change, protects birds and wildlife, and ensures clean drinking water for future generations.  D&R Greenway’s mission is centered on connecting land with people from all walks of life. www.drgreenway.org; info@drgreenway.org. Follow us on Facebook and Instagram.

  • Liz Cutler with Princeton Day School Garden
  • Summer Night Garden
  • David and Goliath

There is no charge to attend; reservations are required at info@drgreenway.org or  (609) 924-4646. 

Categories
Art & Life Business Culture Education Government Lifestyle Perspectives Science

The future of leadership: Manage promises, not people

TAMPA, Fla. — The root cause of many problems facing organizations today, including lackluster performance, is a shortage of standards of behavior, according to management trainer Eric Papp.

 

Most managers would likely agree that far too much time is spent grappling with time-consuming, frustrating challenges that arise when team members don’t follow through on commitments.

 

In his new book, Manage Promises Not People: How to Create a Self-Managing Team, Papp unpacks the inefficiencies of micromanagement and shares ways for leaders to create a culture of ownership and personal accountability by raising the bar of behavior.

 

“Micromanagement is what happens when you manage the person instead of their promises,” Papp said. “When we honor our promises and ensure others do the same, we make things happen and feel more in control and confident.”

 

One of North America’s top management trainers, Papp has worked directly with thousands of managers and delivered over 350 professional training programs to corporate and private clients. His mission is to help leaders uncover effective skills that can lead to more productive, harmonious and successful outcomes.

 

In Manage Promises Not People, Papp reminds readers of the importance of accountability, integrity and honoring one’s word through stories, examples and exercises that can help anyone become a more effective leader.

 

Chapters explore:

• The disappointing trend of diminishing promises;

• Creating a culture of ownership;

• Honoring your word (and the impact of not doing so);

• Staying committed while overcoming perfectionism;

• Repairing broken promises; and

• Coaching others to honor their word.

 

Scott Woitas, Senior Manager at Donaldson Company, Inc., said the book “is a must-read for anyone. As a whole, we have lost the fact that ‘our word is our bond,’ and it reflects on our integrity, both in our professional and personal lives. Manage Promises Not People will get you back on track to be the person everyone knows they can rely on because you say what you’re going to do, and you do what you said you were going to do.”

 

About the Author

Eric Papp has been evaluated as one of the top management trainers in North America for his expertise in leadership effectiveness. He earned his B.A. from the University of Notre Dame and founded Agape leadership, LLC, an intellectual capital firm focusing on leadership and sales for business performance, with the sole purpose of guiding leaders and their teams to success. For more information, please visit www.ericpapp.com.

Categories
Culture Digital - AI & Apps Education Lifestyle Technology

How the Internet adapts Google’s algorithms, such as SEO tricks, its many websites now with similar designs 

—  How the Internet reshaped itself around Google’s search algorithms — and into a world where websites look the same.

—  Animations by Richard Parry

 

 

Mia Sato / The Verge:

 

 

As the 14th season of Bravo’s Real Housewives of New York City came to a close this fall, I found myself on Reddit, reading rumors about the marriage and divorce timeline of one of the show’s stars. Redditors wanted more clues about a fishy relationship history to see if they could uncover a cheating scandal.

 

Were divorce papers public record in New York? I wondered. I did a quick Google search to find out.

 

The search results page was filled with my question’s exact words, repeated across site after site — websites for law firms, posts on forums, ads for creepy lookup tools — but the answer to my actual question was harder to find. At the top of the results page on my phone, Google offered two featured snippets of information quoting different websites. The first one: “Divorce records are not public in New York due to the sensitive nature of many divorce proceedings.” The second: “Due to the state’s underlying legislation regarding family law cases, each divorce is a matter of public record.

 

Google bolded both snippets, but it wasn’t clear to me how they squared. I clicked on both.

 

The two law firm websites were part of an ecosystem I didn’t know existed until I accidentally went looking for it. Law firms across different fields — family law, personal injury, employment lawyers — have blogs full of keyword-addled articles being churned out at a surprisingly fast clip. The goal for firms is simple: be the top result to pop up on Google when someone is looking for legal help. The searcher might just end up hiring them.

 

Many of these blog posts are written by people like E., a self-employed content writer who juggles law firm clients that want Google-friendly content. E. does not have a legal background; they’re just a competent writer who can turn in clean copy. They trawl health department records, looking for nursing homes that get citations for neglect or other infractions. Then E. writes a blog post about it for a firm, making sure to include the name of the offender and the wrongdoing — keywords for which concerned patients or families will likely be searching. (E. requested anonymity so as to not jeopardize their employment).

 

“My bosses, they all don’t want anyone else to know that they use me or that we have the specific process that we have,” E. says. Their name is nowhere to be found, but their writing is often the first thing a searcher will see. The pages were made to be found by people like me.

 

Google controls around 90 percent of the search market, by some measures, so it’s too valuable a referral source to just leave up to luck. Search engine optimization — or SEO, the practice of tweaking content and websites to get Google to boost your visibility — is everywhere, including on the page you’re reading now. And once you see it or SEO-ify your own work, like E. has, it’s impossible not to notice.

 

Google’s outsized influence on how we find things has been 25 years in the making, and the people running businesses online have tried countless methods of getting Google to surface their content. Some business owners use generative AI to make Google-optimized blog postsso they can turn around and sell tchotchkes; brick-and-mortar businesses are picking funny names like “Thai Food Near Me” to try to game Google’s local search algorithm. An entire SEO industry has sprung up, dedicated to trying to understand (or outsmart) Google Search.

 

The relentless optimizing of pages, words, paragraphs, photos, and hundreds of other variables has led to a wasteland of capital-C Content that is competing for increasingly dwindling Google Search real estate as generative AI rears its head. You’ve seen it before: the awkward subheadings and text that repeats the same phrases a dozen times, the articles that say nothing but which are sprayed with links that in turn direct you to other meaningless pages. Much of the information we find on the web — and much of what’s produced for the web in the first place — is designed to get Google’s attention.

 

We often hear about the latest engagement hacks on other platforms like Instagram, TikTok, or X, formerly known as Twitter. But Google is consequential above all of these, acting essentially as the referee of the web. Yet deep knowledge of how its systems work is largely limited to industry publications and marketing firms — as users, we don’t get an explanation of why sites suddenly look different or how Google ranks one website above another. It just happens.

 

Bit by bit, the internet has been remade in Google’s image. And it’s humans — not machines — who have to deal with the consequences.

 

1. Site performance and accessibility

There’s an inherent contradiction in what Google promises is the best way to succeed on Search. Publicly, Google representatives like search liaison Danny Sullivan give a simple, almost quaint answer to business owners who want help: you just need to make great content for people, not Google’s robots.

 

At the same time, Google’s “SEO Starter Guide” is nearly 9,000 words long with dozens of links to additional material. There are several SEO industry publications, plus an untold number of scrappy blogs, marketing firms, and self-proclaimed SEO gurus promising to demystify Google’s black box algorithm. Small business owners must either learn how to do SEO or hire someone — even multiple people or special firms — to do it for them. It’s expensive, time consuming, and often confusing work, and failure to learn the ropes could mean trouble if your traffic begins to tank unexpectedly. Google executives like Sullivan often respond to the folk wisdom of the SEO industry with a six-word incantation meant to absolve them of the industry’s worst practices: that’s not what the guidelines say. It can feel like the guidelines are there to protect Google’s reputation, not actually help anyone get search traffic.

 

Optimizing pages for Google isn’t inherently a bad thing. Google uses its influence over the web to push for objectively good results, like fast-loading sites and accessibility features like alt text on images, which can help audiences understand what’s on a page if an image doesn’t load or if readers use assistive technology like screen readers. Google’s Core Web Vitals metric pushes down sites with certain kinds of intrusive ads or which have slow-loading ads that cause content on the page to shift around.

“[Google’s changes] did sort of homogenize the design of the internet.”

 

Perhaps Google’s most benevolent push has been toward a fast, mobile-first web that has forced small and large publishers alike to overhaul their publishing platforms. But even that effort has come with collateral damage — see the entire news industry reluctantly embracing Google’s AMP format — or in the case of smaller blogs, a flattening and whitewashing of web design across the board.

 

Valerie Stimac Bailey, a professional blogger of a decade, remembers in 2021 when Google began using a new metric to rank sites, called “page experience,” that emphasized giving readers a “delightful” web to browse. Passing Google’s Core Web Vitals tests became all the more important — Google would look at load times, interactivity, and whether visual elements would move around unexpectedly.

 

Bloggers like Stimac Bailey, along with an untold number of other site operators and web companies, saw the writing on the wall: Google might not like your old site, with its giant logos and custom fonts, or the ads that cause text to jump around. Companies like Mediavine, a popular ad-management company, released web design frameworks optimized for this new Google metric and Stimac Bailey, like many others, switched and redesigned her site. But she found the new theme “sterile,” she tells me, and it lacked customization options. It didn’t feel like part of her brand.

 

“I get that that probably was the impetus for a lot of people with really old, slow themes that were not handling mobile well to move to something that was faster for the world of the mobile-first indexing and internet,” Stimac Bailey says. “That was a good impact… but simultaneously, it did sort of homogenize the design of the internet.”

 

Stimac Bailey, who in the past published up to 11 blogs at a time, has experimented with different website themes. All eight of her current sites look nearly identical — her Alaska travel blog Valerie & Valise looks the same as Site School, a blog where she shares data-heavy analyses of how her portfolio of websites is performing.

 

“People spent a lot of money, and a lot of time, and a lot of heartache and stress and psychology redesigning websites,” Stimac Bailey says.

 

Taking Google’s advice on creating good, fast, accessible websites sounds nice in theory; why not do what the search engine prefers and help your readers in the process? Creators I spoke to acknowledged that changes sometimes benefit Google and readers alike. But the line between what’s good for the search algorithm and what’s good for audiences has become blurry over time, and in some cases, the two are treated essentially as the same thing.

 

2. Page design and structure of articles

The small, behind-the-scenes changes site operators deployed over the years have made browsing the web — especially on mobile — more frictionless and enjoyable. But Google’s preferences and systems don’t just guide how sites run: Search has also influenced how information looks and how audiences experience the internet. The project of optimizing your digital existence for Google doesn’t stop at page design. The content has to conform, too.

 

Take, for example, the question-based subheadings that are rampant on pages ranging from personal finance explainers to travel tips to annual event reminders. Sections like “When should I make IRA contributions?” or “What states are getting rid of Daylight Savings time?” will cascade down a page, presumably to help a reader scan for information. But subheadings are also a piece of information Google uses to understand what a page is about and to rank it in Search. Historically, subheadings have been an easy, fast way to juice content for maximum visibility.

 

Some bloggers and outlets scrape the “People Also Ask” panel on search results pages for ideas: the Google-curated section spits out strangely worded or oddly specific questions like, “What is the healthiest vegetable 2023?” and “What two vegetables can be eaten raw?”

 

Sean Bromilow, a food writer based in Canada, has reformatted his blog posts in hopes that Google will pick up his content for placement in these fields. On a page for cucamelons, he added an FAQ section featuring questions like, “How do you eat cucamelons?” and “Are cucamelons a GMO?”

 

“I did that in direct response to Google’s [People Also Ask questions] that they introduced,” he says.

 

Some creators scrape the “People Also Ask” panel for story ideas

A Q&A format might often be the most effective way to write a story or share information — I’ve done stories in this format, too. But other times, question-based subheadings are harder to read, repeating the same phrases without adding anything substantial. Browse this article about gua sha, a massaging technique with roots in traditional Chinese medicine, and you’ll find headings including, “What is a gua sha,” “What are the benefits of a gua sha,” “How to find your gua sha,” and “How to use your gua sha.”

 

A table of contents, too, has become a common sight, appearing at the top of articles. On a post about animals to look out for in Alaska, for example, Stimac Bailey has 10 sections in the table of contents, each linking to the corresponding part of the blog post. Having a linked table of contents allows readers to skip to the part they most want to read, like if someone is strictly interested in seeing caribou.

 

But the table of contents sections also work as jump links on Google Search that appear below the headline and other metadata. Stimac Bailey gets a reasonable amount of traffic to her Pacific Coast Highway guide, not from searchers clicking the title but through people clicking on one of the jump links below. Some SEO strategists even debate whether bloggers should leave their table of contents expanded or collapsed for maximum SEO juice. Stimac Bailey keeps hers collapsed but recently heard from a person selling SEO services that your table of contents should be auto-expanded.

 

“At a certain point, I don’t care if it costs me time on site or it costs me ad views or costs me bounce rate or whatever it might be,” she says. “I like my site to look the way I want it to look, so that’s what I’m going to do.”

 

But many websites just do what they think Google wants or what’s being recommended by SEO experts, even if there’s no guarantee it will work. Google is both overbearing with manuals and withholding of clear answers. Give too much away, and everyone could game the system. In that void, creators and website operators throw things at the wall to see what sticks. And once they start designing their page for Google, it’s easy for their content to be fashioned for Google, too.

 

3. Keyword research and what content is made

For publishers handcuffed to Google Search traffic, there’s often no reason to produce content if people aren’t searching for it. So marketers, writers, and bloggers use a suite of keyword research tools to assess whether there’s enough interest to write the article or make the video in the first place. The result is that publishers end up producing a mountain of material, with Google keywords essentially acting like the assigning editor.

 

When Stimac Bailey writes for her London travel blog, for example, she strategically picks topics that the site will be able to rank highly for — keywords and topics that are too competitive get put on the backburner.

 

“[My writers and I] work on picking topics together, but we need them to be productive because not only am I [monetizing them], I’m paying people for their work, and I’m trying to pay very fairly for that work,” she says. “It’s like, ‘I gotta find these low-competition, high-volume, magic keywords.” For a popular destination like London, those magic keywords don’t really exist.

 

Catherine Cusick understands this tension well. Cusick worked in media for years — including in SEO — before creating the Self-Employed FAQin March. The subscription-driven business acts as a help guide for people who are new to self-employment or who simply have a specific question they can’t get an answer to elsewhere.

 

Most of Cusick’s answers to queries like “Do I need an accountant?” or “What are my healthcare options?” are behind a paywall, so she curates a small number of unlocked articles meant to give prospective customers a sampling of what she offers. These are what Cusick calls “SEO plays.”

 

For these articles, she is only targeting long-tail keywords — lengthier search terms that are often more specific and, as a result, have fewer people searching for them and are less competitive.

 

“The keyword search term that I am going for is, ‘How to pay yourself from a single member LLC.’ My game is entirely long-tail keywords,” she says. “I’m not even competing with ‘How to pay myself LLC.’ Like, that’s too high of a term for me, let alone something like ‘LLC.’”

 

Cusick wrestles with the disconnect between who her business is for — scared, uncertain people trying to make a living — and the SEO requirements she needs to fulfill. Time strategizing and reading technical manuals can feel like time “stolen” from making in-person connections and writing paywalled articles meant to help people through self-employment.

 

“I will need to have a different page for humans, and then another page that’s more of a directory that points humans who’ve arrived to the directory to other pages that will tell them a story,” she says. “The directory page can be structured in a way that makes search engine crawlers satisfied.” In Cusick’s view, we’re asking one piece of content to do too much: fulfill all the SEO requirements and do the careful, uninterrupted work of getting real answers to a reader.

 

I rewrote my prose over and over, but it didn’t seem to satisfy my robot grader

In an emailed statement, Google spokesperson Jennifer Kutz offered a dozen links to public documentation around search, along with generalities about keeping content “helpful” and “relevant.” All points underscored the company’s most common refrain: make content for human audiences.

 

“We’ve given longstanding guidance to create content that’s first and foremost helpful, and we work very hard to ensure that our ranking systems reward content designed for people first. Many sites perform well on Search simply by creating this helpful content, without undertaking extensive SEO efforts,” Kutz tells The Verge. “We continuously refine our ranking systems, and where we identify areas we can improve in ranking people-first content, we prioritize them. For more than a year, we’ve had focused efforts to show more content based on first-hand experience in Search, and to reduce content created solely for search engines, and this work continues.”

 

Kutz did not comment on my questions around specific strategies outlined in this piece, saying that giving granular guidance might make creators “lose sight” of the people-first guidance put forth by Google. Instead, the advice is for website operators to “ask themselves if [a tactic] would be helpful for someone visiting their site.”

 

But in order to be helpful to readers, website operators need people to visit their site in the first place. Fine-tuning content to match exact search terms is a common strategy that can entice users to click on a page that looks like it will answer their question. That doesn’t guarantee content will be better or even good — and sometimes, how users search can create an echo chamber of errors, oft-repeated misinformation, or poorly researched content.

 

One instance of errors multiplying sticks out to Bromilow, the food writer. For a while, he says that Google was returning a litany of incorrect information about Ethiopian cardamom, or korarima. Though black cardamom and korarima look similar, their flavors are not. Websites and writers — and by extension, Google results — were confusing the ingredients. At one point, Bromilow says the first picture on Google Images was of the wrong plant.

 

“If people are searching the wrong thing because that’s what they’ve been given, how do you return a result to them that explains that they’re incorrect, while also being found by them?” Bromilow says. “You don’t want to reinforce the mistake, right? It’s really weird and complicated.”

 

That Ethiopian recipes are being translated from Amharic to English also brings a host of problems: how should Bromilow spell the names of dishes? Should he use whatever spelling people are searching for the most? A post on savory pancakes sums it up, in which the Canadian Bromilow explains why he’s opted to omit the “u” in savoury: “The choice, while it breaks my maple-syrup filled heart, is obvious — savory is searched for more often, and using that spelling is more likely to [get] a recipe noticed by the all-powerful and oft-mysterious search engine algorithms.”

 

To understand what pure SEO-optimized writing looks like, I put my recent story about Google-optimized local businesses through an SEO tool called Semrush that’s reportedly used by 10 million people.

 

Among its suggestions: write a longer headline; split a six-sentence paragraph up because it’s “too long”; and replace “too complex” words like “invariably,” “notoriety,” and “modification.” Dozens of sentences were flagged as being confusing (I disagree) — and it really hated em dashes. I rewrote my prose over and over, but it didn’t seem to satisfy my robot grader. I finally chose one thought per sentence, broke up paragraphs, and replaced words with suggested keywords to get rid of the red dots signaling problems.

 

The result feels like an AI summary of my story — at any moment, a paragraph could start with “In conclusion…” or “The next thing to consider is…” The nuance, voice, and unexpected twists and turns have been snuffed out. I’m sure some people would prefer this uncomplicated, beat-by-beat version of the story, but it’s gone from being a story written by a real person to a clinical, stiff series of sentences.

 

Now imagine thousands of website operators all using this same plug-in to rewrite content. No wonder people feel like the answers are increasingly robotic and say nothing.

 

 

Read more

 

 

Techmeme

Categories
Business Culture Economics Education Healthcare International & World Lifestyle Perspectives Regulations & Security

Organon affirms 2023 revenue and Adjusted EBITDA guidance; also provides 2024 outlook

Regular dividend to remain primary capital allocation priority

  • For full year 2023, the company expects revenue and Adjusted EBITDA margin to be within the ranges provided on Nov. 2, 2023
  • For full year 2023 the company expects free cash flow before one-time spin-related costs to be above previously provided range
  • For full year 2024, the company expects revenue to grow in the low-single-digit range on a constant currency basis, and to achieve stable to improving Adjusted EBITDA margin
  • The company’s annual dividend of $1.12 per share remains its primary capital allocation priority, followed by a balance of discretionary debt repayment and opportunistic business development

 

 

JERSEY CITY, N.J. — (BUSINESS WIRE) — Organon (NYSE: OGN) on Tuesday affirmed prior revenue and Adjusted EBITDA guidance, indicated that free cash flow before one-time spin-related costs is expected to be above the high end of the previous guidance range, and provided high-level financial objectives for 2024.

 

Kevin Ali, Organon’s Chief Executive Officer and Matthew Walsh, Organon’s Chief Financial Officer, will discuss these updates as part of a webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference to be held tomorrow, Jan. 9, 2024, at 4:30 p.m. E.T./1:30 p.m. P.T.

 

Updates to 2023 Financial Guidance Previously Provided on Nov. 2, 2023

For full year 2023, the company is affirming prior revenue and Adjusted EBITDA margin guidance in the ranges of $6.15 billion to $6.25 billion and 30.5% to 31.5%, respectively. Full year 2023 free cash flow before one-time spin-related costs is expected to be above the high end of the previously provided range of $700 million to $800 million.

 

The information presented above reflects the company’s preliminary estimates subject to the completion of the company’s financial closing procedures and any adjustments that may result from the completion of the quarterly and annual review of the company’s consolidated financial statements. Organon will report its full year 2023 results and more fulsome 2024 outlook on Feb. 15, 2024.

 

Preliminary Full Year 2024 Outlook

For full year 2024, Organon expects constant currency revenue growth in the low-single-digit range and stable to improving Adjusted EBITDA margin, which it expects to achieve, in part, through operating expense management.

 

Capital Allocation

The company’s annual dividend of $1.12 per share remains its primary capital allocation priority. Organon has generated, and expects to continue to generate, more than ample cash flow to service its dividend. The company expects to continue to use its remaining free cash flow to achieve its additional capital allocation objectives, which include discretionary debt repayment and the acquisition of assets that enhance Organon’s growth profile.

 

Webcast Information

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the company’s presentation at the J.P. Morgan Healthcare conference on Jan. 9th at: https://jpmorgan.metameetings.net/events/healthcare24/sessions/49500-organon/webcast?gpu_only=true&kiosk=true.

 

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

 

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

 

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.

 

Cautionary Note Regarding Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles “(GAAP).” Specifically, the company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, and free cash flow before one-time spin-related costs which are not recognized terms under GAAP and are presented only as a supplement to the company’s GAAP financial statements. This press release also provides certain measures that exclude the impact of foreign exchange. We calculate foreign exchange by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. The company believes that these non-GAAP financial measures help to enhance an understanding of the company’s financial performance. However, the presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these non-GAAP measures may not be comparable to other similarly titled measures of other companies.

 

The company uses non-GAAP financial measures in its operational and financial decision making and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful representation of the underlying operating performance of the business.

 

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects, including preliminary full-year 2023 financial results, full-year 2024 guidance, and future cash flows and capital requirements, as well as statements concerning Organon’s capital allocation and expense management plans, future dividend payments, , and ability to acquire assets that enhance Organon’s growth profile. Forward-looking statements may be identified by words such as “believes,” “expects,” “will,” “would,” “potentially,” “foresees,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “preliminary” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

 

Risks and uncertainties include, but are not limited to, an inability to fully execute on our product development and commercialization plans within the United States or internationally; an inability to adapt to the industry-wide trend toward highly discounted channels; changes in tax laws or other tax guidance which could adversely affect our cash tax liability, effective tax rates, and results of operations and lead to greater audit scrutiny; an inability to execute on our business development strategy or realize the benefits of our planned acquisitions; efficacy, safety, or other quality concerns with respect to marketed products, including market actions such as recalls, withdrawals, or declining sales; political and social pressures, or regulatory developments, that adversely impact demand for, availability of, or patient access to contraception or fertility products; general economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations; general industry conditions and competition; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; developments that result in changes to Organon’s capital allocation priorities; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (“SEC”), including the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2022 and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).

 

Cautionary Note Regarding Preliminary Financial Information

The 2023 full year results set forth in this press release are still preliminary estimates and subject to Organon’s detailed quarter and year-end close procedures. Organon’s consolidated financial statements as of, and for the three and twelve months ended Dec. 31, 2023, are not yet available. Accordingly, the information presented in this press release reflects the company’s preliminary estimates subject to the completion of the company’s financial closing procedures and any adjustments that may result from the completion of the quarterly and annual review of the company’s consolidated financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in the company’s consolidated financial statements for 2023 when they are completed and publicly disclosed. These preliminary estimates may change, and those changes may be material. The company’s expectations with respect to its unaudited results for the period discussed above are based on management estimates. The company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary estimates and, accordingly, does not express an opinion or any other form of assurance about them.

Contacts

Media Contacts:

Felicia Bisaro

(646) 703-1807

Kate Vossen

(732) 675-8448

Investor Contacts:

Jennifer Halchak

(201) 275-2711

Alex Arzeno

(203) 550-3972

Categories
Business Education Lifestyle Perspectives Regulations & Security

Best’s Review presents Guide to Understanding the Insurance Industry

OLDWICK, N.J. — (BUSINESS WIRE) — Best’s Review starts the new year with the publication of the Guide to Understanding the Insurance Industry as the January edition of the magazine.

 

A high-level overview designed with students, new employees and prospects in mind, the Guide furthers the magazine’s mission to inform readers about the workings of the insurance industry, particularly in the United States. New features for this year include a section on delegated underwriting authority enterprises and resources to help readers navigate the global insurance industry, such as lists of U.S. college risk management and insurance programs, industry publishers, podcasts and more.

 

Also included in the January edition are interviews conducted by AM Best TV with a variety of industry leaders throughout 2023:

 

Best’s Review is AM Best’s monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. Access to the complete content of Best’s Review is available here.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2024 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Patricia Vowinkel
Executive Editor, Best’s Review®
+1 908 882 1771
patricia.vowinkel@ambest.com